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a b s t r a c t
Background: Immunological differences between males and females in response to viral vaccines are well
known. This the first review to examine them for the Human Papilloma Virus.
Methods: We conducted a systematic review andmeta-analysis of the immunogenicity of the Quadrivalent
Human Papilloma Virus Vaccine qHPVV. We searched Medline, Embase, and CENTRAL for trials published
until September 17, 2019. Inclusion criteria were 3-doses and reporting geometric mean titers (GMTs).
We performed random-effects meta-analyses and meta-regression separated by age group and sex.
Results: Our search yielded 1809 unique studies. 334 full texts were screened and data from 18 studies
were extracted. Females had higher pooled geometric mean titers than males in all age groups. Log trans-
formed GMTs inmale children (<16) years were: against HPV6: 662 (95% CI 629–694; I2 = 860%), against
HPV11: 707 (95% CI 690–723; I2 = 63.1%), against HPV16: 853 (95% CI 828–878; I2 = 730%), and against
HPV18 721 (95% CI 708–734; I2 = 264%). In females: against HPV6 710 (95% CI 679–741; I2 = 966%),
HPV11: 732 (95% CI 715–750; I2 = 906%), HPV16: 871 (95% CI 852–891; I2 = 902%), and HPV18 735
(95% CI 711–758; I2 = 927%). In the meta-regression, the sexual difference was significant for HPV6
(p = 0022) with a similar tendency for HPV11 (p = 0066) and HPV18 (p = 0079). Immunogenicity was sig-
nificantly higher in children (<16) than in adults (p < 0001).
Conclusion: Females have higher antibody titers against HPV after receiving the qHPVV than domales. The
difference is bigger in low-risk HPV strains. Adjusting the doses and schedules for each sex should be
explored further.
 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Human Papilloma Virus (HPV) infection remains the most com-
monly diagnosed sexually transmitted infection worldwide [1].
There are more than 100 HPV virus types, which can be separated
into two different risk groups depending on the outcome of the
infection. Infections with a low-risk HPV (LR), such as HPV 6 and
11, are mostly inconspicuous but can cause benign papilloma [2].
High-risk types (HR), on the other hand, are highly carcinogenic
and cause oropharyngeal and anogenital cancers [2]. A substantial
proportion of oropharyngeal, anal, penile, vaginal, and vulvar can-
cers, and practically all cervical cancers, are associated with HPV
infection [3,4]. HPV-related cancers are less common in men,
who suffer 0.8% incidence of penile carcinoma and 0.5% of anal can-
cer [5]. However, HPV DNA was detected in 42% of penile carcino-
mas, in up to 90% of anal carcinomas, and in 100% of condylomas,
meaning that HPV infections can still be a major source of morbid-
ity and mortality in this group [6,7]. Furthermore, HPV seems to be
responsible for 20.6% of all oropharyngeal cancers worldwide, and
up to 21.6% in North America [8,9].
Since it was approved for medical use by the FDA in 2006, the
HPV vaccine has been an efficient preventive measure against
HPV infections and related cancers [10]. As genital warts were
associated with a high economic burden for many countries and
with a high psychosocial burden for those afflicted, most countries
opted for the quadrivalent vaccine [11]. Clinical trials proved that
the quadrivalent HPV vaccine (qHPVV) is efficacious in preventing
infection and dysplasia caused by HPV 6, 11, 16, and 18 [12,13].
Most of these trials were conducted on women, but some included
men as well. However, there is a substantial body of evidence that
the immunological response to foreign and self-antigens differs
between males and females [14]. In fact, one of the most conserved
sex differences in immunology is the difference in humoral immu-
nity (i.e., antibody response) [14]. These sex-based immunological
differences contribute to variations in the response to vaccines
between males and females, with females showing greater vaccine
efficacy than males [15]. Antibody responses to seasonal influenza,
for example, are twice as high in women than in men [16]. This dif-
ference is particularly relevant for the HPV vaccine because
females have higher titers of antibodies against natural HPV infec-
tions, and a larger proportion of females are seropositive (17.9% in
females compared to7.9% in males) [17,18]. This sex difference
with higher antibody responses in females was also observed in
other sexually transmitted viral infections that can be prevented
by vaccination, as hepatitis B [9,15,19].
Antibody responses remain the standard test for vaccine
immunogenicity and the protection established by vaccines is lar-
gely mediated by antibodies [20,21]. We, therefore, reviewed and
analyzed the immunogenicity of the qHPVV, and compared it
across the two sexes and two age groups (younger or older than
16).
2. Methods
2.1. Search strategy and selection criteria
We searched library databases MEDLINE, EMBASE, and
Cochrane and screened bibliographies of included articles. Addi-
tional references were screened according to the same selection
process as those found in the primary search. We did not set any
language restrictions or a time limit to dates of published articles.
We conducted the literature search on April 18, 2018 and updated
it on September 17, 2019.
To capture studies on the immunogenicity of the HPV vaccine,
we developed the search terms: ‘‘Human Papillomavirus‘‘ or ‘‘HPV”
plus ‘‘Vaccine‘‘ plus ‘‘randomised” or ‘‘randomized‘‘ or ‘‘controlled”
plus ‘‘trial‘‘ or ‘‘follow up” or ‘‘cohort‘‘. We also assessed abstracts
from relevant conferences.
Eligible studies had to be randomized controlled trials or con-
trolled trials that assessed the immunogenicity of the qHPV vac-
cine. All participants had to be healthy and HPV-negative at the
beginning of the study. We excluded studies on populations that
include HIV positive patients, HBV positive patients, or patients
with any other infectious disease. We only included studies that
reported their results as the geometric mean titers (GMT) and
the associated confidence interval and used a competitive
Luminex-based immunoassay (cLIA) to assess the antibody level
in the blood. The vaccine had to be administered in a 3-dose sched-
ule over 6 months (one dose at month 0, 1, and 6 respectively) and
GMT measured at the end of the sixth month. This outcome was
used as the indicator for qHPVV immunogenicity. We included
all age groups, but the results had to be reported separately for
males and females to enable comparison between the sexes.
LA and VMH independently screened the studies and extracted
the data using the online Covidence program [22]. The first screen-
ing phase was based on the titles and abstracts. We then assessed
the full text of the relevant studies to reach a final decision about
inclusion or exclusion. Disagreements were resolved by discussion.
We extracted the relevant data into a standardized spreadsheet
that included: funding, country, authors’ affiliation, study methods,
population characteristics, study design, baseline characteristics
(age, sample size, and serostatus), and outcomes (GMTs at month
7).
2.2. Bias risk assessment
We assessed the quality of the included randomized controlled
trials using the Cochrane risk of bias tool [23]. We assessed
sequence generation, allocation concealment, blinding of partici-
pants and study personnel for all outcomes, blinding of outcome
assessors for all outcomes, incomplete outcome data for all out-
comes, and selective outcome reporting, and rated the studies as
high, low, or unclear risk of bias.
2.3. Statistical analysis
We performed random-effects meta-analyses to assess the
mean difference and 95% confidence intervals between log trans-
formed GMTs for each virus (HPV 6, 11, 16,18) and sex separately,
and for adults and children. We assessed heterogeneity between
studies using I2 statistics [24]. We performed meta-regressions
on the results of the meta-analyses, including all studies per virus
type, to assess the significance of the variables sex and age. We
used STATA version 14 (StataCorp, Austin, USA) for all analyses.
2.4. Role of the funding source
The funder of the study had no role in study design, data collec-
tion, data analysis, data interpretation, or writing of the report. All
authors had full access to all the data in the study and shared the
final responsibility for the decision to submit for publication.
3. Results
Our search yielded 2915 studies. After removing duplicates,
1805 unique studies remained. 1475 were excluded through title
and abstract screening because they were not relevant to the pre-
sent study. The full texts of the remaining 334 studies were
assessed and 316 were excluded (see flowchart in Fig. 1 for details).
Through screening the bibliographies of the assessed full-text arti-
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cles, four additional articles were found. Eighteen studies, includ-
ing three clinical trials and 15 randomized controlled trials, met
our inclusion criteria. Included studies came from North and Latin
America, Europe, Africa, and East Asia. Ten studies included female
subjects only, six studies male subjects only, and two both female
andmale subjects. Ten studies were conducted on adults (>16 years
old), five on young adolescents (<16 years old), and three on both
age groups.
The estimated mean antibody-titers in adult women were
based on eight studies that presented GMTs from competitive
Luminex-based immunoassay testing with accompanying CIs in
women older than 16 [25–32]. The pooled geometric mean titer
estimate in women after qHPVV was as follows: 642 against
HPV6 (95% CI 621–662; I2 = 986%, p < 00001), 660 against
HPV11 (95% CI 645–675; I2 = 972%,p < 00001), 800 against
HPV16 (95% CI 785–816; I2 = 969%,p < 00001), and 642 against
HPV18 (95% CI 621–663; I2 = 983%,p < 00001). Five studies pre-
sented similar data on the GMTs in men older than 16 [33–37].
Accordingly, the pooled geometric mean titer estimate in men after
qHPVV was as follows: 620 against HPV6 (95% CI 602–638; I2 =
927%,p < 00001), 646 against HPV11 (95% CI 625–667; I2 = 95
5%,p < 00001), 789 against HPV16 (95% CI 772–805; I2 = 923%,
p < 00001), and 620 against HPV18 (95% CI 596–644; I2 = 947
%,p < 00001) Figure Supplementary Fig. S2, Supplementary
Fig. S4, Supplementary Fig. S6 and Supplementary Fig. S8.
In children <16 years of age, nine studies reported correspon-
dent data; five in females [26,38–41] and four in males
[35,38,39,42]. In female children, the pooled geometric mean titer
estimates were: 71 against HPV6 (95% CI 679–741; I2 = 966%,









Records identified through database search
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(n = 334)
Fig. 1. Flow chart of studies showing inclusion and exclusion of studies at every review step, and reasons for exclusion.
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p < 00001), 871 against HPV16 (95% CI 852–891; I2 = 902%,
p < 00001), and 735 against HPV18 (95% CI 711–758;
I2 = 927%, p < 00001). In male children, the corresponding esti-
mates were: 662 against HPV6 (95% CI 629–694; I2 = 860%,
p < 00001), 707against HPV11 (95% CI 690–723; I2 = 631%,
p < 00001), 853 against HPV16 (95% CI 828–878; I2 = 730%,
p < 00001), and 721 against HPV18 (95% CI 708–734;
I2 = 264%, p < 00001).
Results from meta-regression of immunogenicity data included
all studies per virus type independently of age and sex. These anal-
yses showed that age is the most significant factor affecting the
geometric mean titer in both sexes (p < 00001) (Table 3). Regard-
less of age, females had significantly higher GMTs than males
against HPV 6 (p = 0022). Although 95% confidence intervals over-
lapped in the meta-analyses, females showed a tendency for higher
titers than males for HPV 11 (p = 0066) and and HPV18 (p = 0079)
(Table 3).
At least half of the studies did not report sufficient information
to be able to exclude a potential bias regarding sequence genera-
tion of randomization, concealment of allocation, and blinding of
participants and/or study personnel. Therefore, bias in these stud-
ies cannot be excluded (for details see Table 2). All but two studies
were financed by pharmaceutical companies (Table 1).
4. Discussion
Despite the efficacy and safety of the HPV vaccines in prevent-
ing cervical cancer, many questions remain unanswered, especially
Table 1
Description of included studies.
Author(s) Location Design Sex Age Funding Source
Castellsague 2011 [25] Multicenter
(7 countries)
RCT Women 34.3 ± 6.3 Merck & Company, Inc.
Dobson 2013 [26] Canada RCT Women
Girls
19.3 ± 2.8 12.3 ± 1.4 Ministries of Health in the provinces of
British Columbia, Nova Scotia, and Quebec




11.9 ± 1.9 Merck & Company, Inc.




Merck & Company, Inc.
Kang 2008 [27] Korea RCT Women Girls 9–23 Merck & Company, Inc.




Merck & Company, Inc.
Lin 2014 [36] USA RCT Men 21.4 ± 2.2 Merck & Company, Inc.
Mikamo 2019 [34] Japan RCT Men 22.6 ± 2.1 Merck & Company, Inc.
Mugo 2015 [28] Ghana, Kenya, Senegal RCT Women Girls 9–26 Merck & Company, Inc.
Murata 2019 [42] Japan RCT Boys 12.2 ± 2 Merck & Company, Inc.
Neuzil 2011 [40 Vietnam RCT Girls 12.1
(10.8–4.2)
Bill & Melinda Gates Foundation
Pinto 2019 [37] Multiple (USA, Mexico) Clinical Trial Men 38
(27–61)
Merck & Company, Inc.
Ruiz-Sternberg 2018 [29] Multiple
(18 countries)
Clinical Trial Women 21.9 ± 2.5 Merck & Company, Inc.
Sudenga 2017 [30] South Africa RCT Women 16–24 Merck & Company, Inc.
Tay 2008 [31] Asia Pacific
Non-Asia Pacific
Clinical Trial Women 21 ± 5
20 ± 4
Merck & Company, Inc.
VanDamme 2016 [35] Belgium, Germany, Netherlands RCT Men 16.4 ± 0.5
22.1 ± 2.3
Sanofi Pasteur MSD
Vesikari 2015 [41 Multiple
(6 countries)
RCT Girls 11 ± 1
14.3 ± 0.8
Sanofi Pasteur MSD
Villa 2005 [32] Multiple RCT Women 20.2 ± 1.7 Merck & Company, Inc.
Table 2















Castellsague 2011 RCT low low low low low low low
Dobson 2013 RCT low unclear unclear low low low low
Ferris 2014 RCT low low low low low low low
Hillman 2012 RCT low unclear low low low low low
Kang 2008 RCT unclear unclear unclear unclear low low low
Li 2012 RCT unclear unclear unclear unclear low low low
Lin 2014 RCT unclear unclear unclear unclear low low low
Mikamo 2019 RCT low low low low low low low
Mugo 2015 RCT unclear unclear unclear unclear low low low
Murata 2019 RCT low low low low low low low
Neuzil 2011 RCT Low unclear unclear unclear low low low
Pinto 2019 Clinical Trial
Ruiz-Sternberg 2018 RCT low low low low low low low
Sudenga 2017 RCT unclear unclear low low low low low
Tay 2008 Clinical Trial
VanDamme 2016 RCT low low low low low low low
Vesikari 2015 RCT low low low low low low low
Villa 2005 RCT low unclear low low low low low
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regarding the difference in the vaccine‘s immunogenicity between
the two sexes. To our knowledge, this is the first systematic review
of the effect of sex on the immunogenicity of the quadrivalent HPV
vaccine. Our results suggest that the qHPVV is more immunogenic
in females than in males, and more immunogenic in children than
in adults.
We found that females, regardless of age group, had higher
titers after vaccination than males did. Although not confirmed
for HPV vaccination, sex differences in humoral responses to viral
vaccines have been reported often and many physiological expla-
nations have been proposed [43]. The protective effect of the Bacil-
lus Calmette-Guerin (BCG) vaccine in children (recommended in
countries endemic with TB) was more marked in girls [44,45].
Stronger humoral responses in females were also found after the
hepatitis B (HBV) vaccination [9,15,19]. A retrospective cohort
found that in men and in elderly women, more than 5% of subjects
did not respond properly to the HBV vaccine and showed a steeper
decline in antibody titers [46]. Interestingly, HBV can also be trans-
mitted sexually. Many biological mechanisms contributing to the
sex difference in response to viral vaccines have been described.
T-cells isolated from women exhibit higher cytotoxic activity than
T-cells isolated from men [47], and females show greater antibody
responses in general [9]. Sex hormones affect the function of
immune cells in a dose-dependent manner [48]. While estrogens
promote antibody production by B cells, androgens and proges-
terone inhibit antibody production by B cells [49]. Additionally,
epigenetic and genetic factors affect the immune response to vac-
cines, as indicated by the immune response difference before pub-
erty [14]. The X chromosome contains a large number of immune-
related genes that are prone to damage and mutations. These
mutations are more likely to be expressed in males since they have
one copy only of the X chromosome, while females benefit from
two copies that are unlikely to carry the same mutations [50].
Other than the general reasons for the sex difference in immunity,
like sex hormones and chromosomes, that influence the immune
response against all infectious diseases, there are specific differ-
ences between females and males that apply only to Sexually
Transmitted Infections [14]. Many STIs are transmitted more effi-
ciently from males to females. For example, the risk of genital her-
pes transmission from a male to a female partner is 19%, whereas it
is 5% for transmission from female to her male partner [51]. After a
single episode of sexual intercourse, a woman has a 60% to 90%
chance of contracting gonorrhea from her infected male partner,
whereas the risk for an uninfected male to get the infection from
his female partner is 20% to 30% [52,53]. The reasons for this differ-
ence include greater exposure in females as a result of pooled
semen in the vagina and greater trauma to the surfaces during
intercourse. Most cases of tubal factor infertility are attributable
to untreated sexually transmitted diseases that ascend along the
reproductive tract and are capable of causing tubal inflammation,
damage, and scarring [54]. In men, semen quality deteriorates with
STIs [55]. These physiological and anatomical differences in sus-
ceptibility and consequences of STIs may have contributed to the
evolution of sex-specific immune responses against these
infection.
Secondly, we found that the sex difference in response to Low
Risk (LR) strains of HPV tends to be stronger than it is to High Risk
(HR) strains. Since the most detrimental outcomes of HPV infec-
tions are malignancies (cervical and oropharyngeal), we had
expected the sex difference in response to the vaccine to be more
pronounced against types 16 and 18 (high risk) than 6 and 11
(low risk). Interestingly, one study pointed out that HR HPV types
use a stealth strategy in which the virus produces relatively few
virions to delay the immune response [56]. Although this strategy
reduces the probability of transmission during sexual contact, it
enables the virus to persist for longer periods, which is usually a
perquisite for causing cancer [57,58]. LR types, on the other hand,
achieve higher transmission per sexual contact by producing larger
numbers of virions [56,59]. In other words, LR strains follow a
high-transmissibility, low-persistence strategy, while HR strains
follow a low-transmissibility, high-persistence strategy. The differ-
ence in transcription rates and transmissibility between LR and HR
strains may contribute to difference in the immune reactivity to
these viruses between the sexes.
Among those considered, age was the most significant factor
affecting the geometric mean titer after vaccination with qHPVV.
In both sexes, GMTs were consistently higher in younger age
groups than older groups. This observation is conformant with
the existing literature on the efficacy and immunogenicity of the
HPV vaccine. In one study, girls between 9 and 13 years of age
who received a 2-dose schedule had 177- to 224-fold higher
GMTs than women between 16 and 26 receiving a 3-dose schedule
[60]. In fact, immunogenicity-bridging studies have established
better immune responses in girls than in women [61]. CDC now
recommends 2 doses of HPV vaccine instead of 3 in 11 or
12 year-old boys and girls [62]. Many explanations have been pro-
posed for this difference in immune response between age groups.
Generally, the immune response after receiving the vaccine is best
if the receiver is naïve to the virus. Therefore, vaccination guideli-
nes recommend vaccination at 11 or 12 (i.e., before sexual debut)
but it can be started from age 9 [63].
This is the first systematic review comparing the immunogenic-
ity of the quadrivalent HPV vaccine between the two sexes. One
strength of this systematic review is that it was based on a compre-
Table 3
Outcomes of meta-analyses of included studies.
Virus Age class Sex N studies Mean GMT (95% CI) I2 (%)
HPV6 children f 5 7.1 (6.79–7.41) 96.6
m 4 6.62 (6.29–6.94) 86.0
adults f 8 6.42 (6.21–6.62) 98.6
m 4 6.20 (6.02–6.38) 92.7
HPV11 children f 5 7.32 (7.15–7.5) 90.6
m 4 7.07 (6.90–7.23) 63.1
adults f 8 6.60 (6.45–6.75) 97.2
m 4 6.46 (6.25–6.67) 95.5
HPV16 children f 5 8.71 (8.52–8.91) 90.2
m 4 8.53 (8.28–8.78) 73.0
adults f 8 8.00 (7.85–8.16) 96.9
m 5 7.89 (7.72–8.05) 92.3
HPV18 children f 5 7.35 (7.11–7.58) 92.7
m 4 7.21 (7.08–7.34) 26.4
adults f 8 6.42 (6.21–6.63) 98.3
m 5 6.20 (5.96–6.44) 94.7
GMT = geometric mean titers, log-transformed.
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hensive search strategy. The limitations arise, however, from the
limitations of the primary studies included. The RCTs were
designed to measure the efficacy and immunogenicity of the qHPV
vaccine but not to compare the immunogenicity between the
sexes. Therefore, many of them lack the power to make this com-
parison. Moreover, there are still too few studies on the immuno-
genicity of the HPV vaccine in men, which resulted in
significantly larger confidence intervals, decreasing the ability to
compare the results. In several studies it was not possible to clearly
separate the groups in children and adults according to our defini-
tion (cut at 16 years of age), so that our results might be slightly
blurred for some studies [27,28]. Furthermore, we focused on the
immunogenicity at the seventh month even though the persistence
of the antibodies in the long term is an important indicator of
immunogenicity. We chose this time point because there are still
too few studies that followed up GMTs in the long term. Even
though our search protocol was comprehensive, and we used
broad search terms, it remains possible that we might have missed
some relevant studies.
None of the included studies had a high risk of bias. Nonethe-
less, the risk of bias was unclear in some. Particularly random
sequence generating was often not explicitly described and there-
fore it was not possible to exclude any source of bias. Concealment
of allocation and blinding of the personnel and outcome assessors
were also not explicitly and clearly described in some trials. We
could not, therefore, exclude the risk of bias in these studies.
HPV vaccination of girls, boys, and women has become standard
in many countries, but several countries still do not vaccinate boys,
and expanding the vaccination programs to include men is still a
matter of discussion. This is particularly relevant to high-risk
groups like men who have sex with men (MSM). Other than being
at high-risk, this group does not directly benefit from herd immu-
nity due to high coverage in females [64]. The sex-difference in the
immunogenicity of the vaccine might be important for under-
standing potential differences in efficacy and side effect between
male and females. This systematic review shows that the number
of studies on the immunogenicity of the HPV vaccine in men is still
small and data is still lacking, but existing studies show a differ-
ence in the immunogenicity of the qHPV vaccine between the
two sexes. This indicates the need to conduct more clinical trials
to bridge the gap between the two sexes. As very few studies show
results in the long term by sex, indicating that the sex differences
might persist at least for some viral types, more long-term studies
might have an impact on immunization strategies [38,65]. In
accordance with previous studies, age was a significant factor
affecting vaccine efficacy and we support recommendations for
early vaccination of girls and boys. We also stress the importance
of clearly describing the randomization and blinding protocols in
publications to exclude any possible sources of bias.
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